UBS Group
KRON

UBS Group’s Kronos Bio KRON Stock Holding History

UBS Group’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,012
Closed -$1.91K – 10496
2024
Q4 		$1.91K Buy
+2,012
New +$1.9K ﹤0.01% 9144
2024
Q2 		– Sell
-20,645
Closed -$26.8K – 9834
2024
Q1 		$26.8K Buy
+20,645
New +$23.5K ﹤0.01% 6782
2023
Q4 		– Sell
-100
Closed -$130 – 9624
2023
Q3 		$130 Buy
+100
New +$162 ﹤0.01% 8824
2023
Q2 		– Sell
-15,091
Closed -$22K – 9298
2023
Q1 		$22K Buy
15,091
+4,166
+38% +$7.99K ﹤0.01% 7012
2022
Q4 		$17.7K Buy
10,925
+10,891
+32,032% +$25.1K ﹤0.01% 7805
2022
Q3 		$0 Buy
+34
New +$153 ﹤0.01% 10648
2022
Q2 		– Sell
-93,236
Closed -$674K – 10645
2022
Q1 		$674K Buy
93,236
+46,940
+101% +$400K ﹤0.01% 4458
2021
Q4 		$629K Buy
46,296
+44,000
+1,916% +$688K ﹤0.01% 4790
2021
Q3 		$48K Buy
2,296
+200
+10% +$4.3K ﹤0.01% 6368
2021
Q2 		$50K Buy
2,096
+93
+5% +$2.35K ﹤0.01% 6431
2021
Q1 		$59K Sell
2,003
-302
-13% -$8.85K ﹤0.01% 6374
2020
Q4 		$69K Buy
+2,305
New +$72.3K ﹤0.01% 5931

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS Group's KRON Position: Q1 2025 in Review

UBS Group sold out of Kronos Bio (KRON) in Q1 2025, closing a stake of 2,012 shares — an estimated $1.91K sold.

UBS Group first reported a position in KRON in Q4 2020 and held it in 12 quarters. The position peaked at $674K in Q1 2022. 47 funds tracked by Wall St. Rank hold KRON as of Q1 2025.

  • UBS Group reported no remaining Kronos Bio position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 2,012 Kronos Bio shares in Q1 2025, an estimated $1.91K.
  • UBS Group first reported a position in Kronos Bio in Q4 2020 and held it in 12 quarters.
  • UBS Group's Kronos Bio position peaked at $674K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.